IP
InvestPlatform
Private investment marketplace
Sign in

Founder case

Innovative Biopharmaceutical Solutions

Jacob Anderson · Thailand · May 29, 2026

Back to founder cases
Biotechnology Thailand Requested capital: $2,930,000

Overview

At Innovative Biopharmaceutical Solutions, we are passionate about transforming the landscape of chronic disease management through innovative therapies. Our lead product, a novel biologic treatment, has shown promising results in preclinical studies, demonstrating its potential to significantly improve patient outcomes while reducing healthcare costs. We have successfully completed initial rounds of funding, allowing us to conduct significant R&D and secure our intellectual property. To date, we have developed a robust pipeline that includes treatments for diabetes and heart disease, both of which are prevalent and demand innovative solutions. Our team has established partnerships with leading research institutions, enabling us to leverage their expertise and resources for accelerated development. We are currently preparing for human clinical trials, with plans to file our Investigational New Drug application (IND) within the next six months. As we stand on the verge of this critical stage, we are seeking an investment of $2,930,000. This funding will allow us to expand our clinical trial initiatives, enhance our laboratory capabilities, and strengthen our marketing strategy as we…

Use of funds

The investment will be allocated to the following areas:

  • Clinical Trials: 50% for patient recruitment, clinical site management, and trial execution.
  • Research & Development: 30% for enhancing laboratory facilities, purchasing equipment, and hiring additional scientists.
  • Regulatory Compliance: 10% for preparing and submitting the IND application.
  • Marketing & Outreach: 10% for developing marketing strategies and materials to create awareness ahead of product launch.

Open case

Open this case to get the detailed business plan and direct contact with the founder or seeker.